Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis
Stephanie von Kutzleben; Gareth Pryce; Gavin Giovannoni; David Baker
Author Information: Neuroimmunology Unit
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.